Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies
Abstract Forkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly associated with therapy resistance and less good patient survival. The chemotherapy options for patients with the most aggressive types of solid cancers remain very limited because of the acquired drug resi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-05-01
|
| Series: | Cell Death Discovery |
| Online Access: | https://doi.org/10.1038/s41420-024-01929-0 |